The recent development of quantitative MRI biomarkers, describing muscle atrophy and muscle fat replacement, has proven that the effect of disease activity in NMD (Neuromuscular Disorders) can be detected earlier and more precisely when compared to methods aiming at describing functional decline. Learn more from AMRA and guest speakers from Fulcrum and Pfizer in our upcoming webinar. Registration opening soon. Questions? Reach out to info@amramedical.com